SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
Valuation | |
---|---|
Market Cap ($M) | 0.85 |
Enterprise Value ($M) | -0.60 |
Book Value ($M) | 10.00 |
Book Value / Share | 13.34 |
Price / Book | 0.08 |
NCAV ($M) | -15.30 |
NCAV / Share | -20.42 |
Price / NCAV | -0.06 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -0.16 |
Return on Assets (ROA) | -0.06 |
Return on Equity (ROE) | -0.12 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 0.45 |
Current Ratio | 0.45 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 2.57 |
Assets | 27.88 |
Liabilities | 17.88 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.00 |
Operating Income | -25.02 |
Net Income | -1.79 |
Earnings Per Share Basic And Diluted | n/a |
Earnings Per Share Diluted | n/a |
Earnings Per Share Basic | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | -15.40 |
Cash from Investing | -0.01 |
Cash from Financing | 12.73 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G/A | Armistice Capital, Llc | 2.55 | 6.87 | |
13G/A | Flynn James E | 0.00 | -100.00 | |
13G/A | Lind Global Fund II LP | 0.40 | -94.44 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
16,576 | 59,526 | 27.85 | |
43,097 | 168,273 | 25.61 | |
31,437 | 266,191 | 11.81 | |
79,932 | 227,525 | 35.13 | |
(click for more detail) |
Similar Companies | |
---|---|
VXRT – Vaxart, Inc. | VYNE – VYNE Therapeutics Inc. |
WHWK – Whitehawk Therapeutics, Inc. | XBIO – Xenetic Biosciences, Inc. |
XCUR – Exicure, Inc. |
Financial data and stock pages provided by
Fintel.io